Five Prime Therapeutics (FPRX) Tops Q3 EPS by 6c

Five Prime Therapeutics (NASDAQ: FPRX) reported Q3 EPS of ($0.93), $0.06 better than the analyst estimate of ($0.99). Revenue for the quarter came in at $200 thousand versus the consensus estimate of $4.9 million.

For earnings history and earnings-related data on Five Prime Therapeutics (FPRX) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• United Community Banks sells equipment finance unit for $1.9 billion
• Sharon AI surges premarket; New Oriental gains, Medline slips